REPLIMUNE

Serial Number 87322937
Registration 5353768
705

Registration Progress

Application Filed
Feb 2, 2017
Under Examination
Approved for Publication
Sep 26, 2017
Published for Opposition
Sep 26, 2017
Registered
Dec 12, 2017

Trademark Image

REPLIMUNE

Basic Information

Serial Number
87322937
Registration Number
5353768
Filing Date
February 2, 2017
Registration Date
December 12, 2017
Published for Opposition
September 26, 2017
Drawing Code
4

Status Summary

Current Status
Active
Status Code
705
Status Date
Aug 26, 2024
Registration
Registered
Classes
005

Rights Holder

Replimune Limited

99
Address
69 Innovation Drive
Milton Park, Abingdon
Oxfordshire OX144RQ
GB

Ownership History

Replimune Limited

Original Applicant
99
Oxfordshire GB

Replimune Limited

Owner at Publication
99
Oxfordshire GB

Replimune Limited

Original Registrant
99
Oxfordshire GB

Legal Representation

Attorney
Melanie Howard

USPTO Deadlines

Next Deadline
711 days remaining
Section 8 & 9 Renewal Due (Principal Register) (Based on registration date 20171212)
Due Date
December 12, 2027
Grace Period Ends
June 12, 2028

Application History

30 events
Date Code Type Description Documents
Aug 26, 2024 NA85 E NOTICE OF ACCEPTANCE OF SEC. 8 & 15 - E-MAILED Loading...
Aug 26, 2024 C15P O REGISTERED - PARTIAL SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK. Loading...
Jun 12, 2024 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Dec 6, 2023 E815 I TEAS SECTION 8 & 15 RECEIVED Loading...
Dec 12, 2022 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Sep 4, 2020 COC. O CORRECTION UNDER SECTION 7 - PROCESSED Loading...
Sep 20, 2018 COC. O CORRECTION UNDER SECTION 7 - PROCESSED Loading...
Sep 10, 2018 EROP I TEAS RESPONSE TO OFFICE ACTION-POST REG RECEIVED Loading...
Apr 11, 2018 PRAM O POST REGISTRATION ACTION MAILED - SEC. 7 Loading...
Mar 28, 2018 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL Loading...
Feb 20, 2018 ES7R I TEAS SECTION 7 REQUEST RECEIVED Loading...
Dec 12, 2017 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Sep 26, 2017 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 26, 2017 PUBO A PUBLISHED FOR OPPOSITION Loading...
Sep 6, 2017 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Aug 19, 2017 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Aug 18, 2017 AMPX O PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Loading...
Aug 14, 2017 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Aug 14, 2017 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 14, 2017 ALIE A ASSIGNED TO LIE Loading...
Aug 4, 2017 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Aug 4, 2017 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Jul 19, 2017 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 11, 2017 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
May 4, 2017 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
May 4, 2017 GNRT F NON-FINAL ACTION E-MAILED Loading...
May 4, 2017 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 27, 2017 DOCK D ASSIGNED TO EXAMINER Loading...
Feb 7, 2017 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Feb 6, 2017 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Biological preparations in the nature of viruses for the treatment of cancer, tumors, [ infectious, ] oncological, [ autoimmune, and immune system ] diseases and disorders; viruses for the treatment of cancer and tumors; viruses for inducing immune response for the treatment of cancer, tumors, [ infectious, ] oncological, [ autoimmune, and immune system ] diseases and disorders; pharmaceutical preparations and pharmaceutical substances for the treatment of [ infectious, ]oncological, [ autoimmune, and immune system ] diseases and disorders; pharmaceutical preparations and pharmaceutical substances used for the prevention and treatment of cancer and tumors; pharmaceuticals, namely, [ anti-infectives ] for the treatment of cancer, tumors, [ infectious, ] oncological, [ autoimmune, and immune system ] diseases and disorders; pharmaceuticals for the treatment of cancer; pharmaceuticals for inducing immune response for the treatment of cancer and tumors; vaccines; immunotherapy products, namely, pharmaceuticals for the treatment of cancer, tumors, [ infectious, ] oncological [ , autoimmune, and immune system diseases and disorders; gene therapy products, namely, therapeutics for the treatment of cancer, tumors, infectious, oncological, autoimmune, and immune system ] diseases and disorders

Additional Information

Other
In the statement, "REG. NO. UK0000320659" should be deleted, and UK0003206593 should be inserted.

Classification

International Classes
005